GH1 and metabolic dysfunction-associated steatohepatitis: Five of these patients with NASH received GH replacement therapy for 6 to 12 months followed by repeat liver biopsy and biochemical assessment; GH therapy significantly improved steatosis and fibrosis compared to pre-treatment histology and reduced ALT and ALT [66].